Health authorities are rolling out a targeted vaccination programme designed to reach approximately one million young people in response to rising concerns about meningitis B infections. The initiative will focus on providing protection to those identified as facing the greatest immediate risk of developing the disease.
Meningitis is an infection affecting the protective membranes surrounding the brain and spinal cord. While it can develop in anyone, the condition is most frequently observed in infants, young children, teenagers, and young adults. The infection can be caused by bacteria or viruses, with bacterial meningitis being less common but significantly more severe than its viral counterpart. Untreated meningitis can progress to invasive disease, which may result in blood poisoning or sepsis. Meningitis B accounts for the majority of severe meningococcal disease cases in the UK. During the 2024-2025 period, there were 378 recorded cases of invasive meningococcal disease.
Symptoms of meningitis include a non-blanching rash, sudden high fever, severe headache, neck stiffness, vomiting, diarrhea, joint and muscle pain, light sensitivity, cold extremities, seizures, and confusion. The condition requires urgent medical attention, as early treatment can be lifesaving. The infection spreads primarily through close personal contact, with transmission occurring via respiratory droplets from coughs and sneezes, saliva exchange through kissing, or sharing of drinks and vaping devices. Some individuals may carry the bacteria without becoming ill but can still transmit it to others.
Two primary vaccines offer protection against meningitis’s main causes. The MenACWY vaccine protects against four bacterial groups and is offered to 14-year-olds, with free access available until age 25. The MenB vaccine protects against meningococcal group B and is recommended for infants at eight weeks, twelve weeks, and one year. Additional vaccines, including those for diphtheria, tetanus, pneumococcal disease, and measles, mumps, and rubella, provide supplementary protection.
The new vaccination programme will offer two free doses of the MenB vaccine to Year 13 pupils and individuals under 25 entering university or residential further education this autumn. Experts note that this population faces elevated risk due to shared living accommodations, and invasive meningococcal disease typically peaks in October and November each year.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI